PARIS--(BUSINESS WIRE)--Regulatory News:
Cellnovo Group (Paris:CLNV) (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces the appointment of Thierry Moulin as the Company’s Chief Financial Officer with immediate effect.
Thierry Moulin joins Cellnovo from the multinational biopharmaceutical company Cellectis, where he served as Chief Financial Officer since 2014, overseeing a $228 million fundraise via a public listing on the Nasdaq in March 2015. During his time at Cellectis he also contributed to an extensive programme of restructuring through mergers, divestitures and reallocation of resources.
Prior to this, Thierry Moulin served as Chief Financial Officer of the Euronext Paris listed company Vergnet SA, as well as Ermewa and Toshiba TEC. Throughout his career Thierry Moulin has specialised in the administrative and financial management of industrial groups such as Süd-Chemie and AIRSEC in France as well as internationally, including in Asia from 2003 to 2007. He worked as an auditor from 1982 to 1986 after graduating from Rouen Business School.
Sophie Baratte, Chief Executive Officer of Cellnovo, commented: “I am delighted to welcome Thierry as the new Chief Financial Officer of Cellnovo. He is an excellent addition to the management team and his significant experience of the biopharmaceutical industry and international capital markets will no doubt prove invaluable to the Company as we continue to progress the development and commercialization of our unique diabetes management system. Our ability to attract a CFO of Thierry’s calibre speaks volumes about Cellnovo’s ambition and potential in the diabetes market.
“I would especially like to thank our interim CFO, Didier Le Normand, who has greatly contributed to the structuration of Cellnovo’s first steps on Euronext C.”
Thierry Moulin, Chief Financial Officer of Cellnovo, commented: “I am excited to be joining Cellnovo at this pivotal point in the Company’s development. I believe Cellnovo’s unique approach to diabetes management has enormous potential and I look forward to working with everyone at the Company to achieve the best possible outcomes for patients and shareholders.”
About Cellnovo (Euronext: CLNV)
An international commercial medical technology company, Cellnovo markets the first mobile, connected all-in-one diabetes management system, a disruptive technology enhancing daily disease management for Type 1 diabetes patients. Cellnovo’s device currently addresses the $2.2 billion insulin pump market and the Company is reviewing the potential for the device to serve other markets. Cellnovo is currently marketing the device in the UK, France and The Netherlands and has a clearly defined commercial and manufacturing strategy supported by strategic partners Air Liquide and Flextronics. Cellnovo is headquartered in Paris, France, with product development facilities in Wales, UK. For further information please visit www.cellnovo.com
About the Cellnovo Diabetes Management System
Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin patch pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.
|
Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV |
|